CM
MDGL icon

Capula Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Capula Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,148
Closed -$354K – 725
2024
Q4 		$354K Buy
+1,148
New +$323K ﹤0.01% 203
2021
Q3 		– Sell
-3,248
Closed -$316K – 982
2021
Q2 		$316K Buy
+3,248
New +$384K 0.01% 565

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capula Management's MDGL Position: Q1 2025 in Review

Capula Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 1,148 shares — an estimated $354K sold.

Capula Management first reported a position in MDGL in Q2 2021 and held it in 2 quarters. The position peaked at $354K in Q4 2024. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Capula Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Capula Management sold 1,148 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $354K.
  • Capula Management first reported a position in Madrigal Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Capula Management's Madrigal Pharmaceuticals position peaked at $354K in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Capula Management's 13F filing for Q1 2025, filed 14 May 2025.